Sign In
Buy SYRS
$0.0002
+0 (+0%)
At Close: Jun 03, 2026
Critical Analysis: Syros Pharmaceuticals (NASDAQ:SYRS) & ADVANZ PHARMA (OTCMKTS:CXRXF)
01:23am, Thursday, 02'nd Apr 2026
Institutional and Insider Ownership 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional owners
Cyclacel Pharmaceuticals (NASDAQ:BGMS) vs. Syros Pharmaceuticals (NASDAQ:SYRS) Head to Head Analysis
01:02am, Wednesday, 11'th Mar 2026
Syros Pharmaceuticals (NASDAQ: SYRS - Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compar
Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
04:05pm, Friday, 28'th Feb 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the “Company”) today announced that its Board of Directors (the “Board”) has approved and the Company intends to p
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
11:27am, Thursday, 14'th Nov 2024
SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
12:11pm, Wednesday, 13'th Nov 2024
Syros Pharmaceuticals Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies
The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions
11:00am, Monday, 04'th Nov 2024
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmace
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmace
The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
11:00am, Saturday, 02'nd Nov 2024
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmace
Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript
02:21pm, Thursday, 31'st Oct 2024
Syros Pharmaceuticals, Inc (NASDAQ:SYRS ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Karen Hunady - Director of Investor Relations and Corporate Communications C
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
07:30am, Thursday, 31'st Oct 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancie
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmace
The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
11:00am, Saturday, 26'th Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmace
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
07:08am, Thursday, 24'th Oct 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies
LOS ANGELES, CA / ACCESSWIRE / October 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmace
